Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 2536 and Gemcitabine in Advanced or Metastatic Pancreatic Cancer
NCT02215044Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2007
- Primary completion
- Dec 2008
01
Overview
Phase 1, open-label, single-arm trial of BI-2536 in pancreatic adenocarcinoma (PDAC), sponsored by Boehringer Ingelheim. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Jun 2007; status: terminated.
02
Drugs
BI-2536
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02215044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215044.